Accreditation Statement
This activity is provided by the American Association of Heart Failure Nurses (AAHFN). The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.
Learning Outcome/ Purpose
This activity focuses on assessing and weighing options for heart failure patients that require more than just GDMT. There are three tracks to choose from: Atypical, Advanced, and AHF in Critical Care. Participants will be familiarized with options for patients who no longer are tolerating GDMT and learn the signs of when to refer someone for Adv HF therapies.
- At the end of this activity the learner will have (self-report) improved confidence assessing and weighing options for atypical, advanced, and patients with AHF in Critical Care that require more than just GDMT.
- Participants will (self) report an increase in confidence recognizing the signs of when to refer someone for Adv HF therapies.
Content Integrity Expectations
This educational activity must adhere to the following requirements:
- Educational materials that are part of accredited education (such as slides, abstracts, handouts, evaluation mechanisms, or disclosure information) must not contain any marketing produced by or for an ineligible company, including corporate or product logos, trade names, or product group messages.
- All recommendations for patient care in accredited continuing education must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options.
- All scientific research referred to, reported, or used in accredited education in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation.
- Evolving topics are presented without advocating for, or promoting, practices that are not, or not yet, adequately based on current science, evidence, and clinical reasoning. Sessions that cover these topics must be clearly identified in the program or agenda.
- Accredited education cannot include unscientific approaches to diagnosis or therapy, or education that promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
- Faculty (speakers or authors) must not actively promote or sell products or services that serve their professional or financial interests during accredited education.
- Only relevant relationships are disclosed to learners prior to the activity.
Contact Hours
Attendees may earn (up to) 6.25 Live contact hours by attending this activity and completing the evaluation.
Claiming Contact Hours
Attendees can earn one nursing contact hour for every hour of educational time. Learners must complete an evaluation to receive contact hours. The evaluation is available after the activity.
Disclosure of Relevant Financial Relationships
The planners and faculty for this activity do not have any relevant relationships to disclose, unless listed below. All relevant financial relationships have been mitigated according to ANCC guidance.
Dr. Christopher Barnett, MD,MPH
Research funding: Merck, Acceleron
Consulting: Bayer
Dr. Ray Hershberger, MD
Clinical site for a BMS/Myocardia clinical trial.
Dr. Mikhail Kosiborod, MD
Research grant from: Astra Zeneca, Boehringer Ingelheim, Pfizer
Honorarium from: Astra Zeneca, Boehringer Ingelheim, Novo Nordisk
Stock Options from: Artera Health, Saghmos Therapeutics
Other Research Support from: Astra Zeneca
Consultant/Advisory Board for: 35Pharma, Alnylam, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Imbria Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Sanofi, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, Youngene Therapeutics
Dr. Valmiki Maharaj, MD
Speakers Bureau: Pfizer
Dr. Satish Misra, MD
Consulting, educational speaking: Medtronic
Consulting: Boston Scientific
Dr. Samer Najjar, MD
Advisor to Abbott
Dr. W.H.Wilson Tang, MD
Consultant for: Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, Renovacor, WhiteSwell, Kiniksa Pharmaceuticals, Boston Scientific, and CardiaTec Biosciences, Intellia Therapeutics
Commercial Support
There is no commercial support for this activity.
